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Abstract 
Therapeutic guidelines of intravenous thrombolysis with tissue plasminogen activator 
(tPA) for hyperacute ischemic stroke are very strict. Because of potential higher risk of 
bleeding complications, the presence of unruptured cerebral aneurysm is a 
contraindication for systemic thrombolysis with tPA. According to the standard CT 
criteria, a 66-year-old woman who suddenly developed aphasia and hemiparesis 
received intravenous tPA within 3 h after ischemic stroke. Magnetic resonance 
angiography during tPA infusion was performed and the presence of a small unruptured 
cerebral aneurysm was suspected at the anterior communicating artery. Delayed cerebral 
angiography confirmed an aneurysm with a size of 7 mm. The patient did not experience 
any adverse complications associated with the aneurysm. Clinical experiences of this 
kind of accidental off-label thrombolysis may contribute to modify the current rigid tPA 
guidelines for stroke. 
 
Introduction 
Intravenous thrombolysis with tissue plasminogen activator (tPA) has been licensed 
for selected patients within 3 h after ischemic stroke in many countries [1, 2], and a recent 
clinical study demonstrated the efficacy and safety up to 4.5 h after stroke onset [3]. 
However, the therapeutic guidelines of intravenous thrombolysis with tPA are very strict 
[1–5].  
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Because of potential higher risk of bleeding complications, the presence of an 
unruptured cerebral aneurysm is a contraindication for systemic thrombolysis with tPA 
[2, 4–7]. In this case study, we report a patient receiving intravenous alteplase within 3 h 
after ischemic stroke according to the standard CT criteria, in whom post-tPA 
investigations detected an unruptured cerebral aneurysm. 
Case Report 
A 66-year-old woman without family history of subarachnoid hemorrhage (SAH) developed aphasia 
and right hemiparesis, and arrived at our hospital 135 min after symptom onset. The baseline National 
Institute of Health Stroke Scale was 10 points and baseline CT showed an early ischemic sign in the left 
frontal lobe (fig. 1). The patient met the guidelines for systemic thrombolysis with tPA [2] and received 
intravenous alteplase 177 min after onset. Magnetic resonance (MR) imaging during tPA infusion 
detected a focal territorial early ischemia in the left frontal lobe on the diffusion image, and MR 
angiography showed no arterial occlusion and a suspected unruptured cerebral aneurysm at the anterior 
communicating artery. The patient gradually improved without adverse complications associated with 
the aneurysm. The patient had mild aphasia without hemiparesis at 90 days, indicating the modified 
Rankin Scale of 1. Delayed cerebral angiography for endovascular coiling after 3-month outcome 
follow-up confirmed an unruptured cerebral aneurysm with a diameter of about 7 mm at the anterior 
communicating artery (fig. 1). 
Discussion 
In this patient, the presence of an unruptured cerebral aneurysm was finally confirmed 
on cerebral angiography after 3-month clinical follow-up, although the presence of the 
aneurysm was suspected by MR angiography during tPA infusion. Therefore, the off-label 
use of tPA was not intentional but accidental. If this patient had undergone MR 
angiography before tPA infusion, she would not have received intravenous tPA [2]. 
However, according to the standard guidelines with the rigid 3-hour therapeutic time 
window [1–5], this patient received intravenous tPA. The patient had no complications 
associated with the aneurysm. 
In clinical practice, standard CT-based thrombolysis with tPA for ischemic stroke may 
occasionally include non-stroke conditions [8]. Utilization of MRI or vascular imaging 
before thrombolysis can provide a higher accuracy of stroke diagnosis [9] and may detect 
the contra-indicated conditions such as cerebral aneurysm or other vascular anomalies. 
However, these additional imaging studies may delay the delivery of tPA. 
In reports on off-label thrombolysis for stroke [4, 5], intentional off-label 
thrombolysis, such as intravenous alteplase for elderly patients over 80 years in Europe or 
for patients with seizure at onset, has been performed. In previous reports [4–7], only two 
patients in whom an incidental unruptured cerebral aneurysm was detected after 
intravenous tPA safely received systemic thrombolysis for stroke. Among about 70,000 
patients receiving systemic thrombolysis for myocardial infarction, none experienced an 
aneurysmal SAH [10]. To our knowledge, only one patient developed an aneurysmal SAH 
after systemic thrombolysis for myocardial infarction [11]. The decision against systemic 
thrombolysis in the presence of an unruptured cerebral aneurysm has no scientific basis 
[4, 5]. In the general population, the incidence of an unruptured cerebral aneurysm has 
been reported to be 3.6–6% [12]. Therefore, many patients with an unruptured cerebral 
aneurysm might safely receive systemic thrombolysis with tPA, although unfavorable 
complications after off-label thrombolysis may have been underreported [5]. The safety of 
systemic thrombolysis with tPA in stroke patients with an unruptured cerebral aneurysm  
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should be further examined, especially with regard to the size and location of the 
aneurysm. 
In conclusion, data collection of both intentional and accidental off-label thrombolysis 
for stroke may contribute to modify the presently applied rigid guidelines. 
 
 
 
 
 
Fig. 1. Baseline CT, MRI during thrombolysis, and delayed angiography. Baseline CT (left top) before 
intravenous thrombolysis shows a subtle early ischemic sign in the left frontal lobe. Diffusion image (left 
bottom) during tPA infusion demonstrates a hyperacute ischemia, and MR angiography (right top) 
shows no arterial occlusions and a suspected small aneurysm at the anterior communicating artery. 
Delayed cerebral angiography (right bottom) detects an unruptured aneurysm with a size of 7 mm at the 
anterior communicating artery. 
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